Richard F. Chambers
Chief Executive Officer at Acxit Lifesciences GmbH
Profile
Richard F.
Chambers is currently the Managing Director at Acxit Lifesciences GmbH and a Member-Supervisory Board at ProBioGen AG.
He previously served as a Director at anwerina AG, a Member-Supervisory Board at curasan AG from 2007 to 2017, and the Chief Financial Officer at Heidelberg Pharma AG.
He obtained his undergraduate degree from Technische Universität Darmstadt.
Richard F. Chambers active positions
Companies | Position | Start |
---|---|---|
ProBioGen AG
ProBioGen AG Miscellaneous Commercial ServicesCommercial Services ProBioGen AG operates as a contract development and manufacturing organization. It specializes in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals. The firm offers services such as cell line development, process development, manufacturing programs, physio-chemical analyses, and cell-based assays. The company was founded by Uwe Marx on June 13, 1994 and is headquartered in Berlin, Germany. | Director/Board Member | - |
Acxit Lifesciences GmbH
Acxit Lifesciences GmbH Investment ManagersFinance Acxit Lifesciences GmbH provides financial and strategic advisory services. The private company is based in Frankfurt, Germany. Richard F. Chambers has been the CEO of the German company since 2004. | Chief Executive Officer | 31/12/2003 |
Former positions of Richard F. Chambers
Companies | Position | End |
---|---|---|
CURASAN AG | Director/Board Member | 28/06/2017 |
HEIDELBERG PHARMA AG | Director of Finance/CFO | - |
anwerina AG
anwerina AG Miscellaneous Commercial ServicesCommercial Services Anwerina AG is a pharmaceutical company based in Germany that specializes in the development of quality drugs and medical technology for the treatment of bone diseases. The Swiss company is experts in the field of osteoporosis and have a patient-centered strategy for the development of unique and cost-effective drugs. The private company offers ASCENDRA® / ASCENDRA® DUO / ASCENDRA® TRIO, which is an injection solution used for the therapy of osteoporosis in postmenopausal women with an increased risk of fractures. The company also focuses on the development of generic drugs for patients with bone metastases in the field of oncology. | Director/Board Member | - |
Training of Richard F. Chambers
Technische Universität Darmstadt | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
HEIDELBERG PHARMA AG | Health Technology |
Private companies | 4 |
---|---|
curasan AG
curasan AG Pharmaceuticals: MajorHealth Technology curasan AG engages in the developing, manufacturing and marketing of regenerative medicine. Its products cover the fields of bone and tissue regeneration, tissue engineering, and wound healing for dental, spinal and orthopedic applications. The company was founded by Hans Dieter Rössler in 1988 and is headquartered in Frankfurt, Germany. | Health Technology |
ProBioGen AG
ProBioGen AG Miscellaneous Commercial ServicesCommercial Services ProBioGen AG operates as a contract development and manufacturing organization. It specializes in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals. The firm offers services such as cell line development, process development, manufacturing programs, physio-chemical analyses, and cell-based assays. The company was founded by Uwe Marx on June 13, 1994 and is headquartered in Berlin, Germany. | Commercial Services |
anwerina AG
anwerina AG Miscellaneous Commercial ServicesCommercial Services Anwerina AG is a pharmaceutical company based in Germany that specializes in the development of quality drugs and medical technology for the treatment of bone diseases. The Swiss company is experts in the field of osteoporosis and have a patient-centered strategy for the development of unique and cost-effective drugs. The private company offers ASCENDRA® / ASCENDRA® DUO / ASCENDRA® TRIO, which is an injection solution used for the therapy of osteoporosis in postmenopausal women with an increased risk of fractures. The company also focuses on the development of generic drugs for patients with bone metastases in the field of oncology. | Commercial Services |
Acxit Lifesciences GmbH
Acxit Lifesciences GmbH Investment ManagersFinance Acxit Lifesciences GmbH provides financial and strategic advisory services. The private company is based in Frankfurt, Germany. Richard F. Chambers has been the CEO of the German company since 2004. | Finance |
- Stock Market
- Insiders
- Richard F. Chambers